



**Notice Regarding Completion of PMDA Face-to-Face Advice
on the Clinical Trial Plan for GPC-1 CAR-T Therapy**

October 19, 2026

REPROCELL Inc. (the "Company") announces that it has completed a face-to-face advice session with the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the clinical trial plan for GPC-1 CAR-T therapy targeting recurrent esophageal squamous cell carcinoma.

The development of this therapy is supported by the Japan Agency for Medical Research and Development (AMED) under its publicly solicited project, "Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy," for which the Company's research and development project, "Development of a Novel GPC-1 CAR-T Therapy for GPC-1 Positive Recurrent and Refractory Solid Tumors," was selected.

Based on the discussions during the consultation, the Company has finalized the clinical trial protocol.

The clinical trial is planned to be conducted at the Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital. The Company will continue making the necessary preparations to submit a Clinical Trial Notification (CTN).

The impact of this matter on the Company's consolidated financial results for the current fiscal year is expected to be minor. Should any matters requiring disclosure arise in the future, the Company will promptly make an announcement.